NEW YORK – UK Biobank said on Monday that it is working with a consortium of 10 biopharmaceutical companies to use Olink's proteomic technology to measure the concentrations of roughly 1,500 plasma proteins in around 53,000 UK Biobank participants.
According to the organization, it will be one of the largest studies of plasma proteomics to date and will support better drug development and improve understanding of disease processes.